FRESENIUS SE & CO. KGAA #FutureFresenius
Company Presentation, March 2024
Safe Harbor Statement
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 2 |
- Company overview
- Strategic update
- Business update Q4/23
- Financial priorities & outlook FY/24
- Attachments
02 03 04 05
#FutureFresenius: Focus on Operating Companies
#FutureFresenius
Operating Companies
Profitability optimization and growth
Investment Companies
Financial value management
Healthcare products | Healthcare services | |
for critically and chronically ill patients | along the care continuum | |
World-class therapies through system-critical healthcare products and services
(Bio)Pharma Platform
MedTech Platform
Care Provision Platform
Project business and services
Dialysis provision and products
Deconsolidation
completed
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 4 |
02 03 04 05
Fresenius Kabi - Accelerating our growth, driving performance
Highly specialized, essential healthcare products with balanced market reach
€3.8B
Pharma
€2.3B
Nutrition
€1.5B
MedTech
€0.4B
Biopharma
- Strong focus on key growth vectors
- Strengthening resilience of Generics and IV Fluids
- Increased transparency and targeted segmentation
- Executing Vision 2026 along '3+1' strategy
- FY 23 Net Sales
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 5 |
02 03 04 05
Fresenius Kabi: Strong relevance and scale across our 4 business units
Overview
Key facts
Segment share
Sales 2023
Pharma | Nutrition | MedTech | Biopharma | |
Hospital-sold generic IV | Enteral and Parenteral | Stationary drug delivery | AIID & oncology biologic | |
Drugs and Fluids | Nutrition products | and therapy devices | drugs (biosimilars) |
#1 global IV Drugs | #1 global | #1 global provider for | > 100% growth | |||
Parenteral Nutrition | blood collection | in biopharma '21-'22 | ||||
#3 global IV Fluids | #2 Enteral Nutrition | #2 Infusion Systems | 10+ assets in the | |||
Europe and China | Europe and LATAM | pipeline | ||||
IV Drugs | Parenteral | TCT | Biosimilars |
IV Fluids | Enteral1 | INS2 | and CDMO |
€3.8B | €2.3B | €1.5B | €0.4B |
1. Including Ketoanalogues 2. Infusion & Nutrition Systems
Source: IQVIA, Fresenius Kabi internal analysis; market data refers to Fresenius Kabi's adressable markets
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 6 |
02 03 04 05
Fresenius Helios - Powerful set of care provision assets
Leading healthcare services delivering value for >24 million patients yearly
€7.3B€4.8B
- Continuing stable margin delivery
- Increased focus on return on capital and cash flow
- Clear strategy for value creation across portfolio
- CMD on June 5, 2024
- FY/23 Net Sales; Eugin Group no longer included in this presentation due to divestment - revenue figures thus do not add up to Helios' reported total revenue
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 7 |
Fresenius Helios: High-quality care provision in Germany and Spain
02 03 04 05
Overview
Key facts
Exemplary services
Sales 2023
Helios Germany | Quirónsalud |
Private stationary and ambulatory | Private stationary and ambulatory care |
care in Germany | in Spain and Colombia |
#1 private hospital chain in | #1 private hospital group in | |||||||||||
Germany | Spain & Colombia | |||||||||||
>5.5 million patients p.a. | ~20.3 million patients p.a. | |||||||||||
86 hospitals | 6 prevention | 59 hospitals1 | ~300 | |||||||||
occupational | ||||||||||||
centers | risk prevention | |||||||||||
~230 medical | ~100 outpatient | centers | ||||||||||
care centers | centers |
€7.3B€4.8B
As of December 31, 2023 | 1 Across Spain and Colombia; incl. 8 hospitals in Colombia |
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 8 |
02 03 04 05
Fresenius is at the heart of healthcare
325
Units Fresubin
clinical nutrition consumed each minute globally
>1000
Health care
projects
completed in 101 countries
>1m
Installed base of infusion pumps globally
140 | ~1.3bn | #1 |
Private | ||
Hospitals in | ||
Infusion | ||
hospital | ||
Germany and | solutions | |
operator in EU | ||
Spain | produced | |
86% | ||
>400M | of medical | |
German | ||
KPIs above | ||
Patient lives | average | |
touched each year | ||
26m | >25% | |
10+ | of global blood | |
Patients choose | donations | |
Pipeline of | collected in our | |
Helios for medical | ||
treatment every | Biosimilars | blood bags |
year |
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 9 |
02 03 04 05
Secular growth in healthcare due to strong underpinning trends
Rising national income
+15% real GDP p. capita in OECD countries 2020-301
Higher prevalence of chronic diseases
84% of 67M deaths globally in 2030 due to chronic diseases4
Aging global population
+40% to 1.4B people >60 years worldwide until 20302
Increasing healthcare spend
>10% share of GDP across OECD countries in 20303
Better access to healthcare
477M more people covered by essential health services today than in 20185
Sources: 1) OECD Long-term Economic Scenarios (2023); 2) UN Ageing & Health (2021); 3) OECD Health at a Glance (2019); 4) McKinsey & Co. (2023); 5) WHO Triple Billion Progress
Company Presentation, March 2024 © Fresenius SE & Co. KGaA Investor Relations | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 12 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 April 2024 08:31:08 UTC.
